Drug Discovery Platform Articles & Analysis
74 news found
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its ...
– a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. ...
The company plans to continue growing its team to power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases. ...
The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software Optibrium a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the ...
About HemoShear Therapeutics HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear’s drug discovery platform, REVEAL-Tx™, enables the Company’s scientists to create best-in-class, biologically relevant human disease models ...
The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases. ...
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada ...
About HemoShear Therapeutics HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear’s drug discovery platform, REVEAL-Tx™, enables the Company’s scientists to create best-in-class, biologically relevant human disease models ...
Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. ...
” About SEngine Precision Medicine SEngine's mission is to deliver innovative precise targeted oncology drugs to individual patients by combining functional precision medicine and drug discovery. ...
“Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug discovery platform and four promising new candidates to go along with our lead asset, IBIO-101, an IL-2 sparing anti-CD25 antibody. ...
The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it looks to dive further into drug discovery. ...
This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019. “In three years, HemoShear has identified two novel therapeutic targets and generated lead compounds for these two completely different strategies to potentially treat gout,” said Robert ...
The transaction marks another important step toward iBio’s mission to bring more – and better – immunotherapies to the clinic, faster, with its continued transformation into a biopharmaceutical discovery and development company. The acquired assets include: AI Drug Discovery Platform: A patented system that ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. ...
“Shirly’s leadership and vision over the last five years have played a vital role building a highly efficient drug discovery organization that today has multiple programs in the clinic,” said Jay Galeota, president and CEO, Kallyope. ...
Therefore, the study of protein ubiquitination plays an important role in cell biology and drug discovery. With the comprehensive advanced platform, Profacgen offers its customers the following services: In Vitro ubiquitin conjugation reactions Profacgen provides services to perform ubiquitin reactions in vitro and analyze the results. ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure that applies its expertise in structural biology and membrane proteins to the drug discovery process, has developed MagHelix™ Structural Biology and SBDD Platform that covers all the mainstream technologies needed to successfully ...
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place ...
ByEnterome
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer ...
ByEnterome